| Company Announcements: (reported by the Company) |
No items found
|
| Elevator Pitch: | QBiotics is solving major health issues for humans and companion animals. We discover, develop and commercialise novel pharmaceuticals based on plant-derived cell-signalling molecules sourced from the Australian tropical rainforest, and underpinned by our discovery platform EcoLogic‚Ñ¢. We simultaneously develop our products for the human and veterinary markets, delivering early to market veterinary products as well as real world animal data that informs and de-risks early stages of our human programmes. We currently have two leading programmes. The first is an oncology drug, tigilanol tiglate, with activity against a range of solid tumours. Tigilanol tiglate is now registered as a veterinary pharmaceutical, brand name STELFONTA, and is marketed in the US, EU, UK and Australia. The drug is also currently in human Phase II clinical development. Our second programme is a pharmaceutical, EBC-1013, that addresses all the requirements for healing chronic and acute wounds. We have a very skilled and enthusiastic team of 61 employees. |
| Category: | Hardware & devices, Health & biotech |
| URL: | http://www.qbiotics.com |
| Operational Status: | |
| ASX Listing Code (if applicable): | |
| Year of Commencement: | 2000 |
| Address: | 165 Moggill Rd, Taringa, 4068, AU |
| State: | Queensland |
| Overseas Operations: | |
| X: | |
| Facebook: | |
| Linkedin: | https://linkedin.com/company/qbiotics-group-limited |
| Founders: |
No items found
|
| Awards won: | |
